Disclosed herein are implantable devices coated with a reagent, and methods of preparing and utilizing such devices. The implantable device may comprise an implantable light conduit. The present disclosure enables a more precise registration between the reagent and the device implanted in the target tissue of a subject.

The present invention provides a composition comprising i) a polypeptide comprising calmodulin and two immunoglobulin superfamily domains, wherein said two immunoglobulin superfamily domains are linked via said calmodulin; ii) a calmodulin binding molecule; iii) ions binding to the Ca.sup.2+ binding site of calmodulin; wherein the binding of said calmodulin-binding molecule and of said ions to said Ca.sup.2+ binding site of calmodulin affects the binding of said polypeptide to an antigen to be bound by said polypeptide. The calmodulin may be a permutated calmodulin. A method for affecting the binding of a polypeptide for an antigen using said composition is also disclosed.

The invention relates to compositions and methods for cMLCK gene transfer. In some aspects, the invention provides compositions and methods for treating advanced heart failure in a subject by cMLCK gene transfer, in particular, by administering to a subject an effective amount of a polynucleotide vector that encodes a cMLCK protein, expressing the cMLCK protein from the polynucleotide vector in the heart cells of the subject, and improving ventricular function of the heart. In other aspects, the invention provides compositions and methods for expressing a cMLCK protein in a subject, in particular, by administering to a subject a polynucleotide vector that encodes the cMLCK protein and expressing the cMLCK protein from the polynucleotide vector in the heart cells of the subject, wherein the subject has advanced heart failure.

The present invention provides a composition comprising i) a polypeptide comprising calmodulin and two immunoglobulin superfamily domains, wherein said two immunoglobulin superfamily domains are linked via said calmodulin; ii) a calmodulin binding molecule; iii) ions binding to the Ca.sup.2+ binding site of calmodulin; wherein the binding of said calmodulin-binding molecule and of said ions to said Ca.sup.2+ binding site of calmodulin affects the binding of said polypeptide to an antigen to be bound by said polypeptide. The calmodulin may be a permutated calmodulin. A method for affecting the binding of a polypeptide for an antigen using said composition is also disclosed.